The discussion examines the progress of MAVERIC, Cardiol's decision to expand enrollment to as many as 150 patients and the anticipated path toward topline Phase III results in 2027. Elsley also discusses what the company learned from its Phase II program and how those findings helped shape the pivotal study now underway.
Recurrent pericarditis is an inflammatory heart condition characterized by recurring episodes of inflammation of the tissue surrounding the heart.Patients can experience chest pain, shortness of breath and repeated recurrences over a period of years. Elsley discusses the limitations of existing treatment approaches and Cardiol's development of CardiolRx as an investigational oral, non-immunosuppressive therapy targeting inflammation associated with the disease.
The conversation also turns to Cardiol's ARCHER program in myocarditis and the company's broader work targeting inflammation and fibrosis in cardiovascular disease. Elsley discusses the potential significance of the myocarditis program alongside MAVERIC and the opportunity Cardiol sees across its cardiovascular pipeline.
Listen to the complete interview with David Elsley on The Ellis Martin Report and Money Talk Radio.
https://www.youtube.com/watch?v=RT7J2g1uKjo
About Cardiol Therapeutics Inc.:
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) is a clinical-stage life sciences company focused on developing therapies targeting inflammation and fibrosis associated with heart disease. The company’s lead investigational drug candidate, CardiolRx, is being evaluated in the pivotal Phase III MAVERIC trial for recurrent pericarditis. Cardiol is also advancing its ARCHER program in myocarditis.
Cardiol Therapeutics trades on the Nasdaq and Toronto Stock Exchange under the symbol CRDL.
About The Ellis Martin Report:
The Ellis Martin Report (TEMR) and Money Talk Radio feature interviews with industry leaders in mining, biotech, energy, and technology. The program is globally syndicated through multiple financial platforms and streaming services.
Source:
Cardiol Therapeutics Inc. The Ellis Martin Report
Contact:
Cardiol Therapeutics Inc.
Investor Relations and Media
Email: investor.relations@cardiolrx.com
Telephone: +1 289 910 0855
Website: https://www.cardiolrx.com